Tercica Announces Poster Presentation at Pediatric Endocrinology Nursing Society 2006 Convention.BRISBANE, Calif. -- Tercica, Inc. (Nasdaq:TRCA TRCA Toronto and Region Conservation Authority TRCA Trademark Remedy Clarification Act TRCA Terminal Radar Control Area (FAA) TRCA Teddy Roosevelt Conservation Alliance ) announced today that it will be presenting updated safety and efficacy data from 321 patient-years of treatment with Increlex(TM) (mecasermin (rDNA origin) injection) from long-term studies of growth failure in children with severe primary IGF-1 deficiency (Primary IGFD) at the Pediatric Endocrinology Nursing Society (PENS) 2006 Annual Convention. This updated dataset was included in the Marketing Authorization Application (MAA MAA abbr. macroaggregated albumin ) that Tercica submitted to the European Medicines Agency The European Medicines Agency (EMEA) is a European agency for the evaluation of medicinal products. Until 2004, the European Medicines Agency was known as The European Agency for the Evaluation of Medicinal Products. Roughly parallel to the U.S. (EMEA (Europe, Middle East, Africa) Refers to that region of the world. For example, one might see products packaged differently for the UK, EMEA and Asia Pacific markets. ) for approval to market Increlex in the European Union European Union (EU), name given since the ratification (Nov., 1993) of the Treaty of European Union, or Maastricht Treaty, to the European Community (EU), and has not been previously presented. The PENS meeting is being held from May 10-13 in Myrtle Beach, South Carolina Myrtle Beach is a city and in Horry County, South Carolina, United States. It is part of the Grand Strand, a stretch of beaches along the South Carolina coastline, and the combined Myrtle Beach-Conway-North Myrtle Beach MSA. . The presentation is entitled: Severe Primary Insulin-like Growth Factor-1 Deficiency: Appropriate Diagnosis and Treatment The presentation will discuss the newly described condition of severe Primary IGFD, along with its appropriate diagnosis and treatment. It will take place as part of PENS on Thursday, May 11 from 5:00 p.m. to 7:00 p.m. in the Oleandar Ballroom at the Myrtle Marriott Beach Resort at Grand Dunes in Myrtle Beach. About Tercica and Increlex Tercica, Inc. is a biopharmaceutical company focused on the development and commercialization of products to improve endocrine health. The company's first product, Increlex(TM) (mecasermin (rDNA origin) injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is the only product approved by the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. for the long-term treatment of severe Primary IGFD. For further information on Tercica, please visit www.tercica.com. Insulin-like Growth Factor-1 (IGF-1) is the principal hormone necessary for statural growth, and is released in response to stimulation by growth hormone. Primary IGFD is diagnosed in children who have normal or elevated secretion of endogenous growth hormone yet are resistant to its effects, and whose height and serum IGF-1 levels are more than two standard deviations below normal. A sub-set of these children, whose height and serum IGF-1 levels are more than three standard deviations below normal, are diagnosed with severe Primary IGFD. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion